{"id":107824,"date":"2026-07-24T18:26:32","date_gmt":"2026-07-24T18:26:32","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/107824\/"},"modified":"2026-07-24T18:26:32","modified_gmt":"2026-07-24T18:26:32","slug":"novartis-earnings-beat-cash-flow-weakens","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/107824\/","title":{"rendered":"Novartis Earnings Beat, Cash Flow Weakens"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/8968346\/novartis-earnings-beat-cash-flow-weakens?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;GuruFocus&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">GuruFocus<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis (<a href=\"https:\/\/finance.yahoo.com\/quote\/NVS\" data-ylk=\"slk:NYSE%3ANVS;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NYSE:NVS&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"stocks_tp\" rel=\"nofollow noopener\">NYSE:NVS<\/a>) <a href=\"https:\/\/seekingalpha.com\/news\/4615704-novartis-beats-top-line-and-bottom-line-estimates-reaffirms-fy26-outlook\" data-ylk=\"slk:beat%20second-quarter%20expectations%20on%20both%20revenue;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;beat second-quarter expectations on both revenue&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">beat second-quarter expectations on both revenue <\/a>and earnings, while reaffirming its full-year 2026 outlook despite weaker free cash flow.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The Swiss drugmaker reported adjusted earnings of $2.41 per share, beating estimates by $0.26. Revenue rose 2.6% from a year earlier to $14.41 billion, coming in about $350 million above Wall Street expectations.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis develops prescription medicines across oncology, immunology, neuroscience and cardiovascular disease. Its performance depends heavily on growth from newer drugs offsetting competition and patent losses across older products.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Free cash flow fell 12% to $5.6 billion, making cash generation the softer part of the quarter. Still, management maintained its forecast for low-single-digit sales growth and a low-single-digit decline in core operating income for the full year.  <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Novartis (NYSE:NVS) beat second-quarter expectations on both revenue and earnings, while reaffirming&hellip;\n","protected":false},"author":2,"featured_media":107825,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[1105,3275,206],"class_list":["post-107824","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-free-cash-flow","tag-gurufocus","tag-novartis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116976365483656440","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/107824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=107824"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/107824\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/107825"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=107824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=107824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=107824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}